Oct 26, 2026 08:01PM
Sep 18, 2026 04:47PM
Sep 18, 2026 04:45PM
Sep 9, 2026 04:30PM
Jul 22, 2026 07:00AM
Jul 22, 2026 07:00AM
Jul 7, 2026 04:23AM InMed amends merger deal with Mentari, files S-4 with SEC
Jul 6, 2026 06:20PM
May 19, 2026 08:06AM
May 19, 2026 08:00AM
May 19, 2026 08:00AM
May 19, 2026 08:00AM
Jun 13, 2025 04:30PM
Sep 30, 2024 08:00AM InMed Pharmaceuticals Reports Full Year Fiscal 2024 Financial Results and Provides Business Update
May 14, 2024 08:30AM
Feb 13, 2024 05:41PM
Sep 29, 2023 01:21PM
May 15, 2023 12:33PM
Feb 17, 2023 05:00PM
Jan 10, 2023 07:32AM
Jan 10, 2023 07:30AM InMed Provides Business Update and Milestones for 2023
Nov 11, 2022 06:51PM
Nov 11, 2022 06:51PM
Sep 23, 2022 12:29PM
Sep 23, 2022 12:29PM
Sep 8, 2022 02:09PM
Sep 8, 2022 02:08PM
Sep 8, 2022 02:08PM InMed Pharmaceuticals Provides Update on its Core Research and Development Programs and BayMedica Business
May 13, 2022 07:30AM
May 13, 2022 07:30AM
Mar 17, 2022 07:31AM
Mar 17, 2022 07:30AM
Mar 17, 2022 07:30AM
Feb 15, 2022 05:40AM
Feb 14, 2022 07:34PM InMed Pharmaceuticals Reports Second Quarter Fiscal 2022 Financial Results and Provides Business Update
Feb 14, 2022 07:34PM
Jan 5, 2022 07:30AM
Jan 5, 2022 07:30AM
Nov 10, 2021 07:30AM
Nov 10, 2021 07:30AM
Nov 3, 2021 07:32AM
Nov 3, 2021 07:30AM InMed Pharmaceuticals Files PCT Patent Application for Treating Neurodegenerative Disease Using a Rare Cannabinoid
Nov 3, 2021 07:30AM
Oct 13, 2021 04:30PM
Oct 13, 2021 04:30PM
Sep 24, 2021 07:30AM
Sep 24, 2021 07:30AM
Sep 17, 2021 07:30AM
Sep 17, 2021 07:30AM InMed Pharmaceuticals and BayMedica Participating in Tribe Public’s Webinar "Accelerating The Commercialization of Rare Cannabinoids"
Sep 13, 2021 07:32AM

1,204,679 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All